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Abstract
Background: Interleukin (IL)-19 has been reported to enhance chronic inflammatory diseases such as asthma but the
in vivo mechanism is incompletely understood. Because IL-19 is produced by and regulates cells of the monocyte
lineage, our studies focused on in vivo responses of CD11c positive (CD11c+) alveolar macrophages and lung
dendritic cells.
Methodology/Principal Findings: IL-19-deficient (IL-19-/-) micew e r es t u d i e da tb a s e l i n e( n a ı ¨ve) and following intranasal
challenge with microbial products, or recombinant cytokines. Naı ¨ve IL-19-/- mixed background mice had a decreased
percentage of CD11c+ cells in the bronchoalveolar-lavage (BAL) due to the deficiency in IL-19 and a trait inherited from
the 129-mouse strain. BAL CD11c+ cells from fully backcrossed IL-19-/- BALB/c or C57BL/6 mice expressed significantly
less Major Histocompatibility Complex class II (MHCII) in response to intranasal administration of lipopolysaccharide,
Aspergillus antigen, or IL-13, a pro-allergic cytokine. Neurogenic-locus-notch-homolog-protein-2 (Notch2) expression by
lung monocytes, the precursors of BAL CD11c+ cells, was dysregulated: extracellular Notch2 was significantly
decreased, transmembrane/intracellular Notch2 was significantly increased in IL-19-/- mice relative to wild type.
Instillation of recombinant IL-19 increased extracellular Notch2 expression and dendritic cells cultured from bone
marrow cells in the presence of IL-19 showed upregulated extracellular Notch2. The CD205 positive subset among the
CD11c+ cells was 3-5-fold decreased in the airways and lungs of naı ¨ve IL-19-/- mice relative to wild type. Airway
inflammation and histological changes in the lungs were ameliorated in IL-19-/- mice challenged with Aspergillus
antigen that induces T lymphocyte-dependent allergic inflammation but not in IL-19-/- mice challenged with
lipopolysaccharide or IL-13.
Conclusions/Significance: Because MHCII is the molecular platform that displays peptides to T lymphocytes and Notch2
determines cell fate decisions, our studies suggest that endogenous IL-19 is a constituent of the regulome that controls
both processes in vivo.
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Introduction
IL-19 is a member of the IL-10 family of cytokines whose
biological role has remained incompletely understood. IL-19 is
thought to be significant for human health because increased IL-
19 levels have been reported in asthma [1,2,3,4]. Furthermore, IL-
19 has also been associated with psoriasis, an autoimmune disease
of the skin [5,6,7,8,9,10,11,12], and rheumatoid arthritis [13]. The
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IL-19, IL-20, and IL-24 [14], that all signal via the transcription
factor Signal Transducer and Activator of Transcription 3
(STAT3) [15,16,17,18], are thought to be mediated by distinct
utilization and expression of receptors: IL-20 receptor A/B (IL-
20RA/B) for signaling by IL-19, 20, 24; and IL-22R/IL-20RB for
signaling by IL-20 and IL-24 [18]. IL-20RB is the most widely
expressed of the IL-19 receptor subunits. In lungs, epithelial cells
and infiltrating immune cells have been reported to express both
IL-20RA and IL-20RB [18]. Hematopoietic progenitor cells and
non-hematopoietic cells like epithelial cells and fibroblasts express
IL-20RA/B, while mature T cells and B cells express the IL-
20RA/B at low levels or not at all [19].
The strongest evidence for the biological significance of IL-19
thus far has been provided by studies indicating that the human
il19 gene (but not the il20 or il24 genes) and the gene for one of its
receptor components, the il20RB, has been under evolutionary
pressure from human pathogens (helminth parasites, bacteria and
viruses) [20]. The same study [20] additionally found evidence of
evolutionary pressure on the human il20RA gene by parasites.
Because the immune response has evolved for protection from
infectious diseases, these findings suggest the significance of IL-19
and both of its receptors for human health.
The immune defense from helminth parasites requires intact T
helper 2 (Th2) responses and the elaboration of Th2 mediators,
such as IL-13 [21,22]. These same immune responses and immune
mediators can produce pathology, most prominently asthma
[23,24,25]. Therefore, both the suggested evolutionary pressure
by parasites on the human il19, IL20RB and IL20RA genes [20]
and the association of IL-19 with asthma [1,2,3,4] imply a critical
role of IL-19 for the control of Th2 responses. To address the gap
in our knowledge of the in vivo role of IL-19 in responses of the
lungs to inflammatory stimuli, the present study was designed to
determine the phenotype of IL-19-/- mice on three background-
strains: 129xBL6, C57BL/6, and BALB/c. Our data indicate that
IL-19 is a constituent of the regulome that controls responses of
CD11c+ cells and monocytes in the lungs in vivo, in particular cell
surface expression of MHCII, CD205 and Notch2.
Results
Endogenous IL-19 affects the cellular composition of
bronchoalveolar lavage (BAL) fluid in 129xBL6 mice
Naive IL-19-/- 129xBL6 mice had significantly decreased
CD11c+ cells in the BAL (Fig. 1A). Although the total cell
number in the BAL in IL-19-/- 129xBL6 mice was significantly
increased relative to wild-type mice (Fig. 1A), it was variable and
overlapped with wild type. A decrease in the abundance of
CD11c+ cells in the airways is typically seen in airway
inflammation, induced for example with lipopolysaccharide,
antigen, recombinant IL-13 or Interferon gamma. In all these
cases of inflammation, the CD11c+ cells demonstrate an activated
phenotype with a 10-100-fold increase in MHCII expression
[26,27,28]. However, as shown in Figure 1B, the decrease in the
abundance of CD11c+ cells in the BAL of IL-19-/- 129xBL6 mice
was not associated with an increase in MHCII expression,
suggesting a unique phenotype of airway CD11c+ cells in IL-
19-/- mice. To understand the nature of the remaining cells in the
BAL samples of IL-19-/- 129xBL6 mice, marker-negative cells
were purified by fluorescent activated cell sorting and studied by
electron microscopy. Cells from the BAL of IL-19KO mice were
eosinophils (Fig. 1C); only debris was harvested from the BAL of
wild type mice. These cells were not degranulated. To determine if
the eosinophils were indicators of tissue inflammation, the lungs of
naı ¨ve IL-19-/- 129xBL6 mice were examined by histology. No
significant inflammation was detected.
Endogenous IL-19 and strain background determine the
abundance of CD11c+ cells in the airways
IL-19-/- mice were backcrossed to C57BL/6 or BALB/c for 6 to
10 times, respectively (Figure S1). In these congenic IL-19-/- mice,
the abundance of CD11c+ cells in the BAL was similar to wild-type
(Fig. 2A). To determine if the decreased abundance of CD11c+ cells
in the BALof IL-19-/-129xBL6 mice wasdueto the environmental
microbial flora, the deficiency in IL-19, or a trait from the 129
mouse strain, we intercrossed IL-19-/- 129xBL6 and IL-19-/-
C57BL6 mice and we back-crossed IL-19-/- 129xBL6 mice with
Figure 1. Decreased abundance of CD11c+ cells in the BAL of naı ¨ve IL-19-/- 129xBL6 mice. (A) Bar graphs (white – wild-type, striped – IL-
19-/-) show means and SEM of numbers of total cells and CD11c+ cells in the BAL. One representative independent experiment of 5 is shown (n=4-5
per group per study), *p,0.05, Mann-Whitney-U test. (B) Dot plots show CD11c versus MHCII staining of BAL cells. The percentages of the gated
CD11c+ cells are indicated. One representative of 20 independent experiments is shown. (C) Electron micrographs of marker negative cells in IL-19-/-
mice. The marker negative cells were purified by cell sorting from a pool of BAL samples from groups of 20 to 25 mice of each genotype: wild type or
IL-19-/-. Note that cells from the BAL of IL-19KO mice were eosinophils. Only debris was harvested from the BAL of wild type mice (not shown).
doi:10.1371/journal.pone.0027629.g001
Interleukin-19 and Lung Antigen Presenting Cells
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27629wild type C57BL/6 mice (Figures S1 and 2). Naı ¨ve F2-intercross
(Fig. 2A) or N2-backcross (Fig. 2B) offspring was analyzed. Despite
the homogeneous environment, the F2-intercross offspring of IL-
19-/- 129xBL6 and IL-19-/- C57BL/6 mice had a variable
abundance of CD11c+ cells in the BAL (Fig. 2A). Approximately J
of the animals demonstrated the characteristic low abundance
(,30%) of the CD11c+ cells in the BAL (Fig. 2A). To dissect the
inheritance of the phenotype, IL-19-/- 129xBL6 mice were
backcrossed to wild-type C57BL/6 mice, the N1 offspring
intercrossed, and the N2 offspring analyzed (Fig. 2B). The
abundance of CD11c+ cells in the BAL was significantly lower in
N2-IL-19-/- mice when compared to N2-wild-type (Fig. 2B, Table
S1). Heterozygous N2 offspring also had lower abundance of
CD11c+ cells in the BAL relative to wild type (Fig. 2B, Table S1) at
a statistically significant level when calculated with the unpaired t
test with Welch’s correction for unequal variances. As in the IL-
19-/- 129xBL6 parent generation, the MHCII expression by the
BAL CD11c+ cells remained at wild type levels (data not shown).
Taken together, the data shown in Figure 2 demonstrated that the
decreased abundance of CD11c+ cells in the BAL of IL-19-/-
129xBL6 mice is determined by the deficiency in IL-19 in
interaction with a trait inherited from the 129 mouse strain.
Endogenous IL-19 regulates the responses of CD11c+
cells to airway challenges with microbial products and
pro-inflammatory cytokine
The population of CD11c+ cells residing in the airways and
lungs is known for their responses to microbial products that result
in a 10-100-fold increase in MHCII expression [26,27,28] as
illustrated in Figure S2. To further understand the role of IL-19 in
regulating responses of CD11c+ cells in the lungs, fully
backcrossed IL-19-/- and wild type mice were studied following
priming and intranasal challenge with the fungal Aspergillus antigen
extract. In wild-type mice we saw the expected shift (30, 33, 35) in
the CD11c+ cell population characterized by very high expression
of MHCII (Fig. 3A, 3B). This increase in MHCII expression by
CD11c+ BAL cells was significantly ameliorated in antigen-
challenged IL-19-/- mice (Fig. 3A, 3B). Similar observations were
made in naive IL-19-/- and wild type mice that were intranasally
challenged with the bacterial cell wall component lipopolysaccha-
ride, or the pro-allergic Th2 cytokine IL-13 (Fig. 3B, 3C). In all
three experimental conditions, BAL CD11c+ cells showed
significant reduced MHCII expression at baseline in IL-19-/-
mice relative to wild type (Fig. 3A-C). This prompted us to study
other MHCII positive cell types that reside in the lungs:
monocytes/macrophages and B cells (characterized by the
CD11b, CD19 and CD45R-B220 markers, respectively). These
cell types also demonstrated decreased MHCII expression at
baseline and following intranasal challenge with IL-13 in IL-19-/-
mice relative to wild type (Fig. 3D, 3E).
Endogenous IL-19 regulates Notch2 expression by lung
monocytes
To identify a potential mechanism by which IL-19 regulates
MHCII expression by CD11c+ cells in the airways, monocytes/
macrophages in the lungs and lung B cells, we studied the expression
of Notch proteins by lung monocytes (CD11b, Ly6C
intermediate cells,
Fig. 4A). Notch signaling has been shown to be a critical regulator of
immune cell fate and immune homeostasis. Lung monocytes are
thought to be precursors of CD11c+ cells in the airways in the resting
state (36). Using antibodies that recognize different epitopes on the
Notch2 molecule, we found that lung monocytes from IL-19-/-
C57BL/6 mice expressed extracellular Notch2 at significantly lower
levels relative to wild-type (Fig. 4B). Intranasal administration of
recombinantIL-19toIL-19-/-miceresultedinsignificantlyincreased
extracellular Notch2 expression by lung monocytes (Fig. 4B). In
contrast, transmembrane/intracellular Notch 2 expression was
significantly increased in IL-19-/- C57BL/6 mice (Fig. 4C).
Bone marrow derived dendritic cells (DCs) cultured in the
presence of IL-19 expressed significantly higher levels of
extracellular Notch2
Under inflammatory conditions, airway and lung CD11c+ cells
are known to be replenished from migrating bone marrow
Figure 2. Strain-dependent decreased abundance of CD11c+ cells in the BAL of naive IL-19-/- 129xBL6 mice. The abundance of CD11c+
cells in the BAL (%) from individual mice is shown for the following parental and offspring strains: (A) IL-19-/- 129xBL6 (blue diamonds); IL-19-/-
C57BL/6 (yellow upright triangles); second generation, intercross F2 offspring from a cross between IL-19-/- 129xBL6 and IL-19-/- C57BL/6 parental
lines (green circles); and for comparison, wild-type C57BL/6 (red squares). (B) Backcross N2 offspring originating from a cross between IL-19-/-
129xBL6 and wild-type C57BL/6 mice. The mice were genotyped and found to be wild type (il19
+/il19
+ purple squares), heterozygous (il19
+/il19
-
yellow downward triangles) or IL-19-/- (il19
-/il19
- blue diamonds). Data from individual mice are shown. Horizontal lines indicate means. Data were
pooled from 4-6 experiments. Statistical analysis was with ANOVA followed by Dunnett multiple comparison test, * p,0.05 for comparison between
N2-wild type and N2-IL-19 -/-.
doi:10.1371/journal.pone.0027629.g002
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characterized by high levels of MHCII. Therefore, we cultured
lineage-depleted bone marrow cells harvested from IL-19-/- mice
in the presence of granulocyte-macrophage colony stimulating
factor (GM-CSF). These culture conditions are known to expand
and differentiate DCs characterized by expression of CD11c and
CD205. We measured extracellular Notch2 expression by DCs
that were identified by the CD205 marker. We found that the
presence of IL-19 in the cultures significantly increased extracel-
lular Notch2 expression (Fig. 4D).
Abnormal CD11c+ cell compartment in the airways and
lungs of naı ¨ve IL-19-/- C57BL/6 mice
All data thus far indicated that IL-19 regulates CD11c+ cells in
the airways and lungs at baseline and the behavior of these cells
following inflammatory challenge. However, in C57BL/6 strain
mice, there was no difference between wild type and IL-19-/- in
the numbers of CD11c+ cells in the BAL or lungs (Table S2). To
understand these data better, the CD11c+ cells were studied for
the expression of CD205, an important DC subset marker
[32,33,34]. In wild type mice, the majority of the CD11c+ cells
from BAL or lungs co-express CD205 at high levels (Fig. 5A, 5C).
In IL-19-/- C57BL6 mice, however, the fraction of CD11c+ cells
in the BAL or lungs co-expressing CD205 was reduced by 3-5 fold
(Fig. 5B, 5D-F). Data of wild type and IL-19-/- C57BL/6 mice did
not show overlap with respect to the frequency of CD11c+
CD205+ cells in the BAL or lungs (Fig. 5E, 5F).
Endogenous IL-19 regulates inflammation and histologic
changes in response to a T cell-dependent-fungal
antigen, but not T cell-independent pro-inflammatory
agents
Because MHCII is the molecular platform that presents
antigen-derived peptides to T cells, we studied T cell-dependent
and T cell independent airway inflammation and tissue remod-
eling changes in the lungs. T cell-dependent responses were
induced by priming and intranasal challenge with Aspergillus
antigen (Fig. S1A). T cell-independent responses were elicited by
the administration of lipopolysaccharide or recombinant IL-13 to
naive mice (Fig. S1B, S1C). We found that the T cell-dependent
Figure 3. Decreased expression of MHCII in antigen presenting cells from the lungs of IL-19-/- mice. MHCII expression was determined
by flow cytometry in CD11c+ cells from the BAL (A-C), in CD11b
int cells from the lungs (D), or in B cells (CD19+, B220+) from the lungs (E). The gating
strategy is shown in Figure S2. Cells were analyzed from primed animals that were challenged with Aspergillus antigen (A, Asp. Ag, shaded symbols)
and from naı ¨ve animals that were challenged with LPS (B, at 1 or 5 mg/dose as indicated, shaded symbols) or IL-13 (C-E, shaded symbols). Control
animals (open symbols) were given saline (PBS) intranasally or saline containing bovine serum albumin (BSA), the carrier protein used to stabilize IL-
13. The experimental schedules are outlined in Figure S1. Wild type and IL-19-/- mice were of the BALB/c (A), or C57BL/6 (B-E) strains. Points
represent data for mean fluorescence intensity measured in cells that were harvested from individual wild type (circles), or IL-19-/- (diamonds) mice
pooled from 2 experiments each. Horizontal lines indicate medians. Significance levels were calculated with the Mann-Whitney-U test.
doi:10.1371/journal.pone.0027629.g003
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measured by the analysis of BAL and histological changes in the
lungs that were significantly ameliorated in IL-19-/- mice relative
to wild type (Fig. 6A, Fig. 7). In contrast, airway inflammation
elicited by the T cell-independent challenges was similar in IL-
19-/- and wild type mice (Fig. 6B, 6C).
Discussion
IL-19 is a member of the IL-10 family of cytokines [15,35]. As
such, one of the expectations of our studies was that IL-19 would
have anti-inflammatory effects, just like IL-10. The notion that IL-
19 can have anti-inflammatory activity has been supported by
recent publications from two groups whose work has focused on
innate immune responses in the colon and responses of vascular
smooth muscle and endothelial cells, respectively [36,37,38,39,40].
Our studies argue against these expectations in the lungs and,
instead, suggest that endogenous IL-19 is a constituent of the
regulome that controls homeostasis in the lungs with respect to
MHCII and Notch2 cell surface expression. In keeping with the
function of MHCII in presenting antigenic peptides to T helper
cells, the decreased MHCII expression in several cell types in the
lungs of IL-19-/- mice was associated with a significantly
ameliorated response to intranasal challenge with a T cell-
dependent microbial antigen, Aspergillus antigen. In contrast, our
studies did not reveal increased or decreased inflammatory
changes in IL-19-/- mice intranasally challenged with the
microbial product lipopolysaccharide or the pro-allergic cytokine
IL-13, both of which induce T cell-independent inflammation.
Different routes of innate challenge, lung (in our studies) or colon
(in the studies reported by Dr. Azuma and colleagues [39,40]),
might have contributed to the apparent difference in the biological
role of IL-19.
IL-19 has been implicated in the pathogenesis of human asthma
by increased levels of this cytokine in the serum of patients [1]. IL-
19 has been shown to increase Th2 cytokine production [1,41],
Figure 4. IL-19 regulates Notch2 expression in lung monocytes and bone marrow derived dendritic cells. (A) The density plot of lung
cells shows the electronic gate used to identify CD11b
int/Ly6C
int lung monocytes. Extracellular (B) or transmembrane/intracellular (C) Notch2
expression (mean fluorescence intensity) by lung CD11b
int/Ly6C
int monocytes is shown from groups of individual wild type (circles) and IL-19-/- (gray
diamonds) mice. The data were pooled from two independent experiments. Horizontal lines indicate medians. (B) The mice were given intranasally
control protein (bovine serum albumin, BSA) solution or IL-19 (Figure S1). (C) Naı ¨ve mice were analyzed. The two experiments had different baseline
mean fluorescence intensity for Notch2 expression. Therefore, mean fluorescence intensities were plotted relative to the respective median value of
wild type mice for each of the experiments and then the data were pooled. (D) Extracellular Notch2 expression by bone marrow derived CD205+
dendritic cells. Bone marrow cells were isolated from 8 individual IL-19-/- mice and cultured in the presence of granulocyte-macrophage colony
stimulating factor (GM-CSF), with or without the addition of IL-19 at 1 or 10 ng/ml as indicated. CD205+ cells were electronically gated and Notch2
expression was determined by flow cytometry. The lines connect the data from each individual mouse. The data were pooled from two independent
experiments. Statistical analysis was with the Friedman test for non-parametric repeated measures (overall p=0.0009) and Wilcoxon matched-pairs
signed rank test (* p,0.01).
doi:10.1371/journal.pone.0027629.g004
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receptor showed increased cytokine elaboration, particularly of the
Th1 type [42]. The latter results could be due to competitive
receptor use by IL-20 and IL-24 that share the IL-20RA/IL-20RB
with IL-19, and that also signal through the IL-22R/IL-20RB
receptor complex, which does not bind IL-19 [18,42]. While IL-19
has been reported to stimulate the production of IL-10 [43], our
data did not indicate a deficiency of IL-10 production in IL-19-/-
mice since we did not see an increase in the sensitivity to
lipopolysaccharide that is typical for the absence of IL-10 [44,45].
Our studies demonstrated a critical role of endogenous IL-19 in
determining the abundance of CD11c+ cells in naı ¨ve 129xBL6
mice. Backcross and intercross experiments demonstrated that this
phenotype was due to the combination of the deficiency in IL-19
and a trait inherited from the 129-mouse strain. This trait
encompassing one or more genes remains to be identified. Careful
examination of CD11c+ cells harvested from the airways or from
the lung parenchyma of C57BL/6 mice revealed a large (3-5 fold)
reduction in the subset that expresses CD205 at high levels. While
CD11c+CD205+ spleen and lymph node DCs are known to be
functionally distinct from CD11c+CD205- DCs [32,33,34], the
segregation of function in the airways and lungs between the
subsets of CD11+ cells expressing high or low levels of CD205
remains to be identified. Together, our findings emphasize the
significance of IL-19 in the regulome that controls the homeostasis
of CD11c+ cells in the airways and lungs in vivo. Our data are
supported by in vitro studies showing that IL-19 induces monocytes
to produce innate cytokines, reactive oxygen species [46] and
auto-induces its own production [43].
Naı ¨ve IL-19-/- C57BL/6 mice that were challenged with IL-13
intranasally showed decreased MHCII expression by lung B cells.
This observation could be related to the decreased expression of
extracellular Notch2 and the increased expression of transmem-
brane/intracellular Notch2 by lung monocytes in naı ¨ve IL-19-/-
mice relative to wild-type. Notch2 is a very large molecule with
complex structure that has an extracellular receptor module and
an intracellular nuclear signaling module. Future experiments will
need to address the question of whether IL-19 determines the
extracellular receptor-ligand binding activity, the intracellular
signaling activity or both functions of the Notch2 molecule.
Notch2 is a receptor that provides essential signals for the
development of specific B cell subsets [47,48,49]. While the role of
IL-19 in determining the expression of Notch receptors in B cells
remains to be determined, our data strengthen the notion that one
of the biological roles of IL-19 is to regulate the stimulation of B
cells [50] and B cell responses in asthma [1].
Our data demonstrate that endogenous IL-19 is a constituent of
the regulome that controls the responses of (a) BAL CD11c+ cells
enhancing cell surface MHCII and CD205 expression, (b) lung
monocytes regulating Notch2 expression, and that (c) exacerbates
airway inflammation and histological changes in the lungs to T-
cell dependent antigen challenge. Airway epithelial cells might
amplify this pro-immunogenic activity of IL-19 because both
human and mouse bronchial epithelial cells show increased
Figure 5. IL-19 regulates the relative size of the CD205+ subset of CD11c+ cells in the airways and lungs of naı ¨ve mice. (A-D) The dot
plots show CD11c (y-axis) vs. CD205 (x-axis) staining of BAL (A, B), and lung (C, D) cells. Representative plots from naı ¨ve wild type (A, C, n=21) and
IL-19-/- (B, D, n=16) C57BL/6 mice are shown. The percentage of cells that express CD11c and CD205 at high levels is indicated. (E, F) Group
comparisons of naı ¨ve C57BL/6 wild type (circles) and IL-19-/- (gray diamonds) mice for percentages of CD11c+ CD205+ cells in the BAL (E) or in cell
suspensions prepared from the lung parenchyma (F). Individual data points that were pooled from two experiments are shown. Horizontal lines
indicate medians. Significance levels were calculated with the Mann-Whitney-U test. Note that the numbers of CD11c+ cells in the BAL and lungs of
wild type and IL-19-/- mice were similar (Table S2).
doi:10.1371/journal.pone.0027629.g005
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IL-4 and IL-13 [3,51] and IL-19 stimulation of Th2 cells results in
increased production of Th2 cytokines [1,41,52].
Our study, together with previously published reports detailing
the significance of IL-19 in infectious [20,53,54], allergic [1,2,3,4]
and autoimmune diseases [5,6,7,8,9,10,11,12,13] suggests a
potential clinical application. Recombinant IL-19 or IL-19
inhibitors might be useful clinically in instances that call for
modulation of MHCII expressing cells and of CD11c+ CD205+
cells in the lungs.
Figure 6. IL-19-/- mice have a decreased inflammatory response to a T cell-dependent challenge of the airways. (A) Groups of IL-19-/-
(diamonds) and wild type (circles) mice were primed with Aspergillus antigen and challenged with antigen intranasally (Asp. Ag, shaded symbols). (B,
C) Groups of naı ¨ve mice were given lipopolysaccharide (B, LPS, 1 or 5 mg/dose as indicated) or IL-13 (C) intranasally shown as shaded symbols.
Control animals received saline (PBS) or control protein (bovine serum albumin, BSA) intranasally (A-C, open symbols). Figure S1 shows the
experimental schedules; Figure S2 the technique for the determination of eosinophils, neutrophils, and CD11c+ cells in the BAL by flow cytometry. IL-
19-/- and wild type mice were of the BALB/c (A), or C57BL/6 (B, C) background strains. Groups of mice were pooled from 2-3 independent
experiments. Individual data are shown. Horizontal lines represent medians. Significance levels were calculated with the Mann Whitney U test.
doi:10.1371/journal.pone.0027629.g006
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Ethics Statement
All animal experiments were performed according to guidelines
outlined by the United States Department of Agriculture and the
American Association of Laboratory Animal Care under the
supervision and specific approval of the Institutional Animal Care
and Use Committees at St. Luke’s Roosevelt Hospital (IACUC
numbers GR0205, GR0206), Columbia University (IACUC number
AC-AAAA7912) and New York University (IACUC number
081114, most recent approval date: 11/17/2010) (New York, NY).
The named IACUC committees specifically approved this study.
Mice
The IL-19-/- mice on the 129xBL6 background were previously
described [55]. The mice were speed-backcrossed to the C57BL/6
for 6 generations or backcrossed to the BALB/c strain for 11
generations. Wild type C57BL/6 and BALBc mice were
purchased from the Jackson Laboratory. To determine environ-
mental or genetic trait influences on the function of endogenous
IL-19, F2 and N2 mice were studied. F2 mice were generated by
crossing IL-19-/- 129xBL6 mice with IL-19-/- C57BL/6 mice
followed by intercrossing the F1 offspring. N2 mice were made by
crossing IL-19-/- 129xBL6 mice with wild type C57BL/6 mice
followed by intercrossing the N1 offspring. The mouse strains are
listed in Figure S1.
The mice were housed in filter-top cages under specific
pathogen-free conditions at St. Luke’s Roosevelt Hospital, New
York, New York, Charles River Laboratories, Wilmington,
Massachusetts, or the Institute for Environmental Medicine,
New York University, Tuxedo, New York. All experiments were
performed according to guidelines outlined by the United States
Department of Agriculture and the American Association of
Laboratory Animal Care under the supervision of the Institutional
Animal Care and Use Committees at St. Luke’s Roosevelt
Hospital, Columbia University or New York University (New
York, New York).
BAL cell analysis by electron microscopy
Marker negative cells were purified by sorting using an Aria
fluorescent activated cell sorter (Becton Dickinson) from a pool of
BAL cells harvested from 20 to 25 mice in each group of naı ¨ve
wild type 129xBL6 mice or IL-19-/- 129xBL6 mice. The cells
were fixed and photographed via electron microscopy at the
Rockefeller University Microscopy Core facility.
Allergen exposure
Groups of mice were either given phosphate buffered saline
(PBS) or primed and intranasally challenged with Aspergillus
antigen known to induce T cell-dependent airway inflammation
and lung tissue remodeling [26,44,56]. Priming with Aspergillus
antigen (crude antigen free of viable fungus) consisted of three
weekly intraperitoneal injections of 100 mg Aspergillus antigen in a
100-ml volume of PBS (Fig. S1A). One week later, challenges were
given intranasally to lightly anaesthetized mice with 100 mgo f
antigen in a 50-ml volume of PBS once. Control groups were given
Figure 7. Histological changes in the lungs of wild type and IL-19-/- mice primed and challenged with Aspergillus fumigatus
antigen. Wild type and IL-19-/- mice were of the BALB/c background strain. Priming and challenge with Aspergillus antigen was as indicated in Figure
S1. Control animals were given saline (PBS) intranasally. (A) Photomicrographs of lung sections from wild type or IL-19-/- mice. The sections were
stained with periodic acid schiff and digitally scanned. The software was used to generate the scale bar (50 mm). Perivascular/peribronchial
inflammation (arrows), pulmonary arterial remodeling (stars) and mucus cell hyperplasia (arrow heads) are indicated. (B) Scores for perivascular/
peribronchial inflammation, arterial remodeling and mucus cell hyperplasia in the lungs of wild-type (circles) or IL-19-/- (diamonds) mice. The gray
boxes outline the values from the groups of control animals depicting the scores spanning the 25% and the 75% quartiles. Dots represent individual
data from Aspergillus antigen primed and challenged mice. Horizontal lines show medians. Three independent experiments were performed during a
time span of 6 years. Therefore, scores needed to be standardized. For this reason, scores were plotted relative to the respective median scores of
primed and antigen-challenged wild-type mice for each experiment and then the data were pooled. Significance levels were calculated with the
Mann-Whitney-U test.
doi:10.1371/journal.pone.0027629.g007
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4 days after the final intranasal exposure to Aspergillus antigen
because our previous work has shown that this is the optimal time
point to assess inflammation and pathologic changes in the lungs
[44].
Lipopolysaccharide
Naive wild-type or IL-19-/- mice were administered lipopoly-
saccharide (Sigma-Aldrich, Minneapolis, Minnesota), or PBS once
as outlined in Figure S1B. Lipopolysaccharide was diluted in
phosphate buffered saline and administered intranasally at doses of
1o r5mg in a 50-ml volume to lightly anaesthetized naı ¨ve mice.
The animals were euthanized one day later.
Recombinant Cytokines
Naive wild-type or IL-19-/- mice were administered recombi-
nant mouse IL-19 (R&D Systems, Minneapolis, MN), or IL-13
(Peprotech) diluted in PBS solution containing bovine serum
albumin, or PBS solution containing bovine serum albumin only
(bovine serum albumin, low in lipopolysaccharide; 2.5 mg/ml;
Sigma-Aldrich) for 3 times at two-day intervals. The cytokines
were administered intranasally at a dose of 5 mg in a 50-ml volume
to lightly anaesthetized naı ¨ve mice as outlined in Figure S1C
[24,26,56]. The animals were euthanized one day following the
last administration of cytokine.
Tissue recovery
At the end of each experiment, the mice were euthanized by an
overdose of barbiturate and tissues were harvested [24,26,56].
BAL was performed by 3 instillations of 1 ml of Hanks balanced
salt solution that was gently retrieved. The left lung lobe was
sutured at the bronchial stem and removed into Hanks balanced
salt solution. A single cell suspension was prepared by gently
mushing the lung tissue using the plunger of a syringe and a cell
strainer, followed by straining through nylon-mesh cell strainers.
The remaining lung lobes were inflated with 0.5 ml of 10%
formaldehyde buffered with PBS and removed into formaldehyde.
Histology
Sections of lungs were stained with hematoxylin and eosin (H&E)
or Periodic Acid Schiff (PAS). The sections were examined under
200x or 400x magnification. Histological changes were scored by
examining 20-40 consecutive view fields as described before
[24,26,56]. Briefly, the scores for peribronchia/perivascular inflammation
were: (0) normal with very few inflammatory cells; (1) scattered
inflammatorycellsuptotwo ringsindepth;(2)cuffsofinflammatory
cells measuring three rings or more in depth; or (3) dense ring of
inflammatory cells. Interstitial inflammation was scored as: (0) normal;
(1) increased numbers of cells within the alveoli; or (2) consistent
increase in the numbers of cells within the alveoli, appearance of
multinucleated giant cells, and thickening of the alveolar septa.
Pulmonary arterial remodeling was scored as: (0) normal; (1) up to a
doubling of the depth vascular wall with intact lumen and circular
media (all cells follow the form given by the endothelium);
(2) thickening of the vascular wall by more than 3 x than normal;
or (3) lumen appears to be obstructed and the wall is thickened and
lined with disorganized layers of cells (cells in the blood vessel wall
assume a pattern that differs from the lumen). Mucus cell hyperplasia
was scored as: (0) normal; (1) less than 30% of the epithelial cells;
(2) .30–70%; or (3) . 70% of the cells lining the airway lumen
were stained with the periodic acid schiff reagent.
Slides were scanned with the Aperio slide scanner to capture
digital images. Aperio software was used that is available for free
download from the aperio website (http://www.aperio.com/
download-imagescope-viewer.asp). Scale bars were generated with
the Aperio software.
Flow Cytometry
Bronchoalveolar lavage (BAL) cells and cell suspensions
prepared from the lung lobes were analyzed by flow cytometry
as described [26,44,56,57] using BD Calibur (BD Biosciences) and
MACS Quant (Miltenyi Biotechnology) instruments and FloJo
(TreeStar Inc) software (Fig. S2).
BAL samples were studied (Fig. S2) for the presence of
eosinophils (CD11b
high, CCR3
high, GR1
low, CD11c
low-intermediate,
MHCII
low-intermediate), neutrophils (CD11b
high, GR1
high,
CD11c
low-intermediate, MHCII
low-intermediate), and CD11c+ cells.
CD11c+ cells were defined in the dot plots depicting CD11c+
staining versus side scatter. The CD205+ subset of CD11c+ cells
was identified by staining with the Dec205 monoclonal antibody
tagged with PeCy7 (Biolegend). Dendritic cells (DCs) were
identified as a subpopulation of the CD11c+ cells that was
MHC II
high and the majority of these cells also expressed CD11b
at high levels [26,27,28,58]. To verify the data obtained by flow
cytometry, aliquots of the BAL samples were spun onto slides using
a cytocentrifuge, stained with Wrightes/Giemsa and analyzed by
microscopy.
Lung cell suspensions (Fig. S2) were studied for CD11c+ cells,
monocytes/macrophages (CD11b
intermediate, CCR3
low, MHC
II
low), monocytes (CD11b
intermediate, Ly6C
intermediate) and B cells
(CD45R/B220
+ and CD19
+).
The cell populations were analyzed, as shown in Figure S2,
using monoclonal antibodies tagged with Pacific Blue, AlexaFluor,
fluorescein (FITC), phycoerythrin (PE), peridinin-chlorophyll
(PerCP), Allophycocyanin (APC), or cyanine (Cy) tandem dyes
that were purchased from BD Bioscience (San Jose, California),
Ebioscience (San Diego, California) or Biolegend (San Diego,
California) as follows: anti-CD11c (clone N418) tagged with PE,
APC, or Pacific Blue; anti-CD11b (clone M1/70) tagged with PE
or APC; anti-MHCII (I-A/I-E, clone M5/114.15.2) tagged with
FITC or biotin (detected with Streptavidin-PerCP); anti-Ly-6G/
Ly-6C (clone GR1) tagged with biotin (detected with Streptavidin-
PerCP) or APC-Cy7; anti-F4/80 (clone 8M8) tagged with APC;
anti-CCR3 (clone TG14, Biolegend, or clone 83103, BD
Bioscience) tagged with AlexaFluor 647.
Expression of Notch2 was analyzed with antibodies detecting
different epitopes of Notch 2. Extracellular Notch2: hamster anti-
mouse Notch2 (clone HMN2-35, Biolegend) purified, detected
with biotinylated anti-Armenian Hamster and Streptavidin-
PerCP; or rat anti mouse/human Notch 2 (clone 16F11,
Ebioscience) tagged with PE. Transmembrane/intracellular
Notch2: rabbit monoclonal anti mouse/human Notch 2 (clone
D76A6, Cell Signaling Technology, Danvers, Massachusetts)
purified, detected with APC labeled donkey anti-rabbit multi-
absorbed antibody (Fab2 fragment, Jackson ImmunoResearch,
West Grove, Pennsylvania).
B cells were detected in the lungs using anti-CD45R/B220
(clone RA3-6B2) tagged with Pacific Blue or PerCP and anti-
CD19 (clone 6D5) tagged with PE-Cy7 or APC.
Bone marrow cultures
Bone marrow cells were harvested from one femur per mouse
and depleted of lineage + cells using anti-Ter119, CD11b, B220,
CD5, GR1 antibodies and magnetic beads. The cells were
harvested and seeded into 96 well plates at a cell density of
50,000 -100,000 cells in a total volume of 200 ml per well. The cell
culture medium was RPMI1640 supplemented with Penicillin
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pyruvate (1 mM), L-Glutamine (2 mM), ß2 mercapto-ethanol
(10 mM) and 10% fetal calf serum. The fetal calf serum lot was
selected for low lipopolysaccharide content. The cells of each
mouse were cultured with granulocyte-macrophage colony
stimulating factor (GM-CSF) at 5 ng/ml, with or without IL-19
at 1 or 10 ng/ml. The cultures were performed in duplicate. The
cells were incubated for 7 days in humidified atmosphere in 5%
CO2. The cells were then directly stained in the wells with anti–
CD205 and anti-Notch2 antibodies and read by flow cytometry.
The cells were gated for CD205 and the mean fluorescence
intensity of extracellular Notch2 was recorded. The mean of the
duplicate wells for each sample was calculated and plotted.
Statistics
Differences between two groups were analyzed using the two-
tailed, unpaired Mann-Whitney-U test. Statistical analysis of
backcross experiments was with ANOVA followed by Dunnett
multiple comparison test. The bone marrow culture study was
analyzed with the Friedman test for non-parametric repeated
measures and the Wilcoxon matched-pairs signed rank test. The
data were analyzed with the GrapPad Prism software. A significant
difference between groups was assumed when the p value was 0.05
or lower.
Supporting Information
Figure S1 Mouse strains studied and experimental
schedules. List of IL-19-/- mouse strains. Schematic represen-
tations of the experimental schedules are shown for (A) Aspergillus
antigen (Asp. Ag) priming by intraperitoneal (i.p.) injections
followed by intranasal (i.n.) challenge, (B) lipopolysaccharide
(LPS), or (C) recombinant cytokine (IL-13 or IL-19) challenge via
the intranasal (i.n.) route of naı ¨ve mice.
(TIF)
Figure S2 Gating strategy for the detection of cell
populations in the BAL and lungs. (A, B) Gating for
CD11c+ cells in the BAL in dot plots demonstrating CD11c
staining (Y-axis) and Side Scatter (X-axis) from a naı ¨ve mouse (A)
or a mouse undergoing Th2 inflammation (B). (C) Dendritic cells
(DCs) identified from the CD11c+ population in plots of CD11c
(Y-axis) and MHCII (X-axis) staining. The overlay dot plot
technique was used to draw a gate that separates CD11c+ cells
that express low levels of MHCII (typical for naı ¨ve control), or
high levels of MHCII (DCs, typically increased in Th2
inflammation). (D) Neutrophils and eosinophils identified in a
dot plot of BAL cells by the expression of GR1 (Y-axis) and
CD11b (X-axis). Neutrophils expressed high levels of GR1 and
CD11b; eosinophils low levels of GR1 and high levels of CD11b.
(E) In neutrophil and eosinophil populations, here shown for
eosinophils, DCs were excluded by gating on cells that are
CD11c
low-intermediate and MHCII
low to intermediate. (F-H) CD11b
int
monocytes (CD11b
intermediate, CCR3
negative-low) in dot plots
showing CCR3 (Y-axis) and CD11b (X-axis) staining of naı ¨ve
BAL (F), naı ¨ve lung (G) or IL-13 challenged lung (H). Eosinophils
(CCR3
high, CD11b
high) and neutrophils (CCR3
low, CD11b
high)
were also distinguished in these plots.
(TIF)
Table S1 Distribution of the abundance of CD11c+ cells
in the BAL from N2 offspring mice.
(DOC)
Table S2 Numbers of CD11c+ cells in the BAL and lungs
and expression of CD205 by CD11c+ cells.
(DOC)
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